A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

Cancer Chemother Pharmacol. 1989;24(3):193-6. doi: 10.1007/BF00300242.

Abstract

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experienced nausea and 8 had moderate vomiting; mild headache occurred in 10 patients. No cardiovascular (including ECG) changes took place. Apart from headache, no neurological side effects occurred.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiemetics / adverse effects
  • Antiemetics / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Drug Evaluation
  • Drug Tolerance
  • Female
  • Granisetron
  • Humans
  • Indazoles / adverse effects
  • Indazoles / therapeutic use*
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Nausea / prevention & control*
  • Neoplasms / complications
  • Neoplasms / drug therapy
  • Pyrazoles / therapeutic use*
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / therapeutic use*
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Indazoles
  • Pyrazoles
  • Serotonin Antagonists
  • Granisetron